| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 6,440 | 29,620 | 147,750 | 140,730 | 235,310 |
| Sales Growth | -78.26% | -79.95% | +4.99% | -40.19% | +33.46% |
| Net Income | 183,450 | -47,580 | -284,230 | -293,650 | -290,020 |
| Net Income Growth | +485.56% | +83.26% | +3.21% | -1.25% | -53.21% |
Kyntra Bio Inc (KYNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO.
Fiscal Year End Date: 12/31